Roth Capital Expects Stronger Earnings for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Investment analysts at Roth Capital lifted their FY2024 earnings per share (EPS) estimates for shares of Sensus Healthcare in a report released on Thursday, November 14th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per share of $0.40 for the year, up from their previous estimate of $0.36. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.38 per share. Roth Capital also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.09 EPS, Q1 2025 earnings at $0.16 EPS and Q2 2025 earnings at $0.19 EPS.

SRTS has been the topic of several other reports. Maxim Group increased their price target on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday. HC Wainwright raised their target price on Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $8.41 on Monday. The business’s 50-day moving average is $6.37 and its two-hundred day moving average is $5.97. The company has a market capitalization of $137.83 million, a P/E ratio of 14.60 and a beta of 1.04. Sensus Healthcare has a fifty-two week low of $2.02 and a fifty-two week high of $8.69.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors have recently modified their holdings of the business. Truvestments Capital LLC purchased a new stake in shares of Sensus Healthcare during the 3rd quarter valued at approximately $32,000. Chapin Davis Inc. purchased a new stake in shares of Sensus Healthcare during the 2nd quarter valued at approximately $53,000. Geode Capital Management LLC raised its position in shares of Sensus Healthcare by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after buying an additional 11,525 shares during the period. Sachetta LLC raised its position in shares of Sensus Healthcare by 12.9% during the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company’s stock valued at $631,000 after buying an additional 13,544 shares during the period. Finally, XTX Topco Ltd raised its position in shares of Sensus Healthcare by 76.0% during the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after buying an additional 13,619 shares during the period. 25.30% of the stock is currently owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.